KSD-101 vaccine for Epstein-Barr virus-related blood cancers
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests an experimental vaccine called KSD-101 for people with blood cancers or lymphomas linked to the Epstein-Barr virus. The vaccine aims to help your immune system fight the cancer or prevent it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older.
- You must have a blood cancer or lymphoma linked to the Epstein-Barr virus (EBV), a common virus that can sometimes cause cancer.
- You have either already tried standard treatment and it didn't work, or you and your doctor agree that this vaccine could help prevent a relapse.
- You cannot have active hepatitis B, hepatitis C, HIV, or syphilis.
- You cannot be pregnant, breastfeeding, or planning a pregnancy within the next year.
- You must avoid certain vaccines (live or weakened) for 4 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies KSD-101 (a vaccine treatment) for people whose blood cancers are linked to EBV and who have not responded or have relapsed after standard treatment. It may help your immune system better control the cancer, especially when other options have already been tried.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
This trial tests a new cell therapy called KSD-101 for nasopharyngeal cancer that has not responded to standard treatments. The therapy is injected into your lymph nodes and works by boosting your immune system to fight the cancer.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
Hear when a new EBV Associated Lymphoid Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.